RIDDLE&CODE
21.9.2021 10:07:10 CEST | Business Wire | Press release
The consortium formed by Dyne.org , RIDDLE&CODE and InfoCert , has been selected by the European Commission as one of seven contractors to develop the next version of the European Blockchain Services Infrastructure (EBSI) .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005128/en/
The award is one more milestone in the consortium's track record of excellence with cryptography and blockchain, after Dyne.org led the flagship H2020 project DECODE , RIDDLE&CODE's blockchain solutions are deployed in banking and utility markets Europe wide and InfoCert being the largest Certification Authority at European level and eIDAS certified QTSP.
The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations. The European Blockchain Partnership aims to scale the investment fund to a fully developed platform with up to €2 billion in funding.
The consortium led by the non-profit foundation Dyne.org is developing a multilayered network of blockchains for distributed secure execution of smart contracts, including edge-computing scenarios deployed on low-power embedded devices and chips. The blockchain-agnostic solution offers compatibility with a wide range of products to grant freedom of choice to participating member states and solution developers. Existing integrations include BigchainDB, Ethereum, Hyperledger Fabric, Hyperledger Sawtooth and Bitcoin.
Dyne.org's Zenroom is the core component of the solution. Its portable and secure smart-contract execution environment works standalone (zero dependency) even in a web browser. It can be programmed in a language similar to plain English and guarantees to be functional and portable for two decades to come. Dr. Francesca Bria , president of the Italian National Innovation Fund Cassa Depositi e Prestiti comments: "Zenroom stands for Citizen Crypto. It is a core part of the DECODE tech stack for Smart Cities and it makes it easy to understand the complexity of data transformation while being compatible with any platform, including Legacy Infrastructure. We make Crypto for Citizens and we make it Open Source. "
Each member of this consortium gathers together a mature experience developing and deploying industrial standards, as well as facilitating open source community adoption of technologies, including the presence in major blockchain standardisation initiatives such as ISO TC/307, INATBA, W3C and Sovrin.
The combination of blockchain-specific hardware solutions for critical infrastructures, developed by RIDDLE&CODE, will help turn data sources into trusted ones and lay the foundation for EBSI's automated processes and scalability. The combination of InfoCert's leadership and scale when providing services for digital trust, security and identity management complying with standards will allow Europe to adopt mature blockchain solutions to mission-critical environments.
For the initial phase of EBSI's procurement, the consortium proposes a revolutionary solution for a European Digital Product Passport . As a path to success, the consortium plans to work actively to create an open "playing field" in Europe that can easily integrate a diversity of solutions and open this promising industrial field to new players from the public and private sectors.
Quote from the consortium members:
● Andrea D'Intino (EBSI Project leader, Dyne.org): "The consortium's unique combined understanding of cryptography, blockchain and identity technologies as well as its global market positioning, give us the tools and the strength to bring EBSI to the next level. We are truly excited to embrace the policy makers, the businesses and the developers into an inclusive community, to fuel their ideas and products into the European Union's blockchain. "
● Thomas Fürstner (Founder & CTO, RIDDLE&CODE): "The blockchain landscape diversifies into layer one and layer two technologies. Layer one is used for attesting values and identities with a small transaction payload and low frequency. Layer two is used for high-volume, low-value, day-to-day transactions. Then, there is the neglected but important layer zero, where blockchain meets products and goods of the physical world. This is exactly where RIDDLE&CODE contributes to EBSI ."
● Carmine Auletta (Chief Strategy and Innovation Officer, InfoCert - Tinexta Group): "Being involved in shaping the future EU blockchain infrastructure not only makes us extremely proud, it also could have an important strategic impact on our reference market. An EU blockchain infrastructure could represent the backbone on which EU Trust will be built in the future. " He further commented: "InfoCert, as the leading Qualified Trust Service Provider in the EU, aims to further strengthen its thought leadership role in a constantly evolving market. InfoCert has an impressive track record in building innovative solutions and an ambitious R&D program focused on Digital Identity and Digital Trust. It includes the exploitation of emerging technologies, among which blockchain is one of the most promising. Our partners have tremendous technical competencies in distributed ledger technologies, while InfoCert has very distinctive expertise in building Trust Frameworks. Joining forces was natural and proved to be crucial in the success of our consortium. "
About RIDDLE&CODE
RIDDLE&CODE is Europe's leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About Dyne.org
Dyne.org is a non-profit foundation dedicated to free and open source software and community development with 20 years of expertise in developing applications used worldwide. Its motto is "we are free to share code and we code to share freedom" and other projects include independent streaming software for free speech, privacy tools for activists and GNU/Linux distributions.
More information: dyne.org
About InfoCert
InfoCert, Tinexta Group, is the largest European Certification Authority, active in over twenty countries. The company provides services in digitisation, eDelivery, Digital Signature and digital preservation of documents and is an accredited AgID digital identity operator in the area of SPID (Public System for the management of Digital Identity). The company holds a 51% stake in Camerfirma, one of the principal Spanish certification authorities and a 16.7% stake in Authada, a leading-edge German Identity Provider.
More information: infocert.digital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005128/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom